Cabergoline is a dopamine receptor agonist drug used to treat hyperprolactinemia and Parkinson's disease. Cabergoline impurities are unwanted substances that may be present in cabergoline formulations as a result of the manufacturing process. These impurities may affect the safety, efficacy, and quality of the drug product, therefore their identification and control is crucial for ensuring the drug's purity and quality. Various analytical techniques are employed to detect and quantify cabergoline impurities, and strict limits are set by regulatory agencies to ensure that the drug product is safe for human use.
